Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096590 · ClinicalTrials.gov registry record
Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 60
- Enrollment target
NCT00096590: Completed study, sponsored by National Cancer Institute (NCI).
NCT00096590 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096590 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
RATIONALE: A test that detects abnormal blood clotting in patients with cancer may help doctors plan cancer surgery. PURPOSE: This laboratory study is looking at a new blood test to detect abnormal clotting in patients with metastatic cancer undergoing surgery.
Interventions
- OTHER laboratory biomarker analysis
- OTHER physiologic testing
- PROCEDURE study of high risk factors
- OTHER immunoenzyme technique
- OTHER coagulation study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-11 |
What the finished NCT00096590 record still lists
NCT00096590 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00096590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096590 about?
NCT00096590 is a clinical study titled "Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery". RATIONALE: A test that detects abnormal blood clotting in patients with cancer may help doctors plan cancer surgery. PURPOSE: This laboratory study is looking at a new blood test to detect abnormal clotting in patients with metastatic cancer undergoing surgery.
What is the current status of trial NCT00096590?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2004-11.
What interventions are being tested in trial NCT00096590?
The interventions under investigation include: laboratory biomarker analysis (OTHER), physiologic testing (OTHER), study of high risk factors (PROCEDURE), immunoenzyme technique (OTHER), coagulation study (OTHER).
Who is sponsoring clinical trial NCT00096590?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia